ReviewPathology oncology research : POR2011
Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
Review in Pathology oncology research : POR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 97 citations in OpenAlex.
- The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation.Scientific reports · 2020Trial
- BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study.EBioMedicine · 2018Trial
- Impact of Epstein-Barr Virus Donor Serostatus on Post-Transplant Mortality and Post-Transplant Lymphoproliferative Disorder in Epstein-Barr Virus Seropositive Thoracic Organ Transplant Recipients: Data from the Organ Procurement and Transplantation Network.Journal of medical virology · 2026Article
- Post-transplant lymphoproliferative disorder presented with diplopia; Diagnosis by FDG-PET/CT.Radiology case reports · 2025Article
- Post-Transplant Lymphoproliferative Disorder Presenting as Biventricular Failure After Heart Transplantation.JACC. Case reports · 2025Article
- Imaging of cystic fibrosis manifestations in the abdomen.Abdominal radiology (New York) · 2025Review
- Multisite Head and Neck Pediatric Posttransplant Lymphoproliferative Disorder: A Case Report.Clinical case reports · 2025Article
- Dynamic Presentations of Recurrent Post-Transplant Lymphoproliferative Disorder in a Heart Transplant Recipient: A Rare Case Study.ACG case reports journal · 2024Article
- Posttransplant lymphoproliferative disorder in a heart transplant recipient: a case report.Indian journal of thoracic and cardiovascular surgery · 2023Article
- Article
- Hematologic malignancies of the gastrointestinal luminal tract.Abdominal radiology (New York) · 2020Review
- Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.European journal of nuclear medicine and molecular imaging · 2020Article
- A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Article
- Article
- Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Article
- Three Hypothetical Inflammation Pathobiology Phenotypes and Pediatric Sepsis-Induced Multiple Organ Failure Outcome.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2017Article
- Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.Molecular neurobiology · 2016Review
- HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation.Transplantation · 2016Article
- Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis.FEBS open bio · 2016Article
- Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD).Journal of gastrointestinal oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a heterogeneous disease group of benign and malignant entities. The new World Health Organisation classification introduced in 2008 distinguishes early lesions, polymorphic, monomorphic and classical Hodgkin lymphoma-type PTLD. Based on the time of appearance, early and late forms can be identified.PTLDs are the second most frequent posttransplantation tumors in adulthood, and the most frequent ones in childhood. The incidence varies with the transplanted organ-from 1%-2% following kidney transplantation to as high as 10% following thoracic organ transplantation-due to different intensities in immunosuppression. Immunocompromised state and Epstein-Barr virus (EBV) infection are the two major risk factors.In Europe and the US approximately 85% of PTLDs are of B-cell origin, and the majority are EBV-associated. Symptoms are often unspecific; extranodal, organ manifestations and central nervous system involvement is common. Early lesions respond well to a decrease in immunosuppression. Malignant entities are treated with rituximab, chemotherapy, radiotherapy and surgical therapy. Adoptive T-cell transfer represents a promising therapeutic approach. The prognosis is favorable in early PTLD, and poor in late PTLD. Five-year survival is 30% for high-grade lymphomas. The prognosis of EBV-negative lymphomas is worse.Lowering the risk of PTLD may be achieved by low dose maintenance immunosuppression, immunosuppressive drugs inhibiting cell proliferation, and special immunotherapy (e.g. interleukin-2 inhibitors). Early detection is especially important for high risk-e.g. EBV-negative-patients, where the appearance of EBV-DNA and the increase in its titer may help.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.